Biogen stock after-hours at EUR 195.34: minus 1.44 percent versus prior close
Published on 10/02/2026 at 22:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Biogen stock was at EUR 195.34 after-hours at 10:57 p.m. CEST on October 2, 2026. The price was down 1.44 percent versus the prior close at Lang & Schwarz, which was EUR 198.19.
Trading day ends lower
Lang & Schwarz also showed a bid of EUR 195.14 and an ask of EUR 195.54. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Biogen stock.
Litifilimab data updated
In a release dated October 2, 2026, Biogen Inc. reported 52-week results from the Phase 2 portion of its ongoing Phase 2/3 AMETHYST study of investigational litifilimab in cutaneous lupus erythematosus. Among participants who received litifilimab from the beginning of the study, 27.2 percent achieved clear or almost clear skin at Week 52, compared with 19.0 percent at Week 24. The company also reported that 28.8 percent achieved a 70 percent or greater reduction in CLASI activity at Week 52, versus 21.7 percent at Week 24. Biogen said no new safety signals were identified.
Third-quarter results scheduled
Biogen said in a September 16, 2026 release that it will report third-quarter 2026 financial results before the market opens on October 28, 2026. The company said management will host a webcast at 8:30 a.m. ET following the release of the financial results.
